drugset / Trial / NCT05983250
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
Phase 3
Recruiting
230 enrolled
Tenax Therapeutics, Inc.
Medpace, Inc. · collabNorthwestern University · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study will evaluate the efficacy of TNX-103 (oral levosimendan) compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance (6 MWD; Day 1 to Week 12).
Timeline
- Start
- 2024-01-10
- Primary completion
- 2026-10
- Completion
- 2028-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | TNX-103 | Unknown | 1 mg | Oral |